Drug Profile
Research programme: oral heparins - Debiopharm
Alternative Names: Oral heparins research programme - DebiopharmLatest Information Update: 12 Aug 2010
Price :
$50
*
At a glance
- Originator Debiopharm
- Class Heparins
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Deep vein thrombosis
Most Recent Events
- 09 Mar 2005 Oral heparins is available for licensing worldwide (http://www.debio.com)
- 09 Mar 2005 Preclinical trials in Deep vein thrombosis in Switzerland (PO)